1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Major Depressive Disorder
Yale UniversitySmall moleculeN/ADormant
D
28/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 65/ 100
Competitive context
130 Active assets in the Major Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
(1S,2R)-MILNACIPRAN Allergan | Phase 4 | BBB |
Vortioxetine Mayo Clinic | Phase 4 | BBB |
Opc-34712 Nova Scotia Health Authority | Phase 4 | BBB |
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL Massachusetts General Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →